GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Jafron Biomedical Co Ltd (SZSE:300529) » Definitions » Debt-to-Asset

Jafron Biomedical Co (SZSE:300529) Debt-to-Asset : 0.31 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Jafron Biomedical Co Debt-to-Asset?

Jafron Biomedical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥549 Mil. Jafron Biomedical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥1,255 Mil. Jafron Biomedical Co's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was ¥5,854 Mil. Jafron Biomedical Co's debt to asset for the quarter that ended in Mar. 2024 was 0.31.


Jafron Biomedical Co Debt-to-Asset Historical Data

The historical data trend for Jafron Biomedical Co's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jafron Biomedical Co Debt-to-Asset Chart

Jafron Biomedical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.01 0.19 0.24 0.30

Jafron Biomedical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.27 0.31 0.32 0.30 0.31

Competitive Comparison of Jafron Biomedical Co's Debt-to-Asset

For the Medical Devices subindustry, Jafron Biomedical Co's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jafron Biomedical Co's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Jafron Biomedical Co's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Jafron Biomedical Co's Debt-to-Asset falls into.



Jafron Biomedical Co Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Jafron Biomedical Co's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(282.46 + 1392.449) / 5543.302
=0.30

Jafron Biomedical Co's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(549.275 + 1254.901) / 5853.64
=0.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jafron Biomedical Co  (SZSE:300529) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Jafron Biomedical Co Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Jafron Biomedical Co's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Jafron Biomedical Co (SZSE:300529) Business Description

Traded in Other Exchanges
N/A
Address
No. 98, Science and Technology 6th Road, High-tech Zone, Guangdong Province, Zhuhai, CHN, 519085
Jafron Biomedical Co Ltd is a China-based company engaged in the research, development, production, and sales of biomaterials and medical devices. It offers solutions for kidney disease, poisoning, rheumatic immune solution, critical illness and liver disease. The company's products include JFYC-100 pre-punching machine, DX-10 blood purifier, and HA resin hemoperfusion.
Executives
Li Feng Director
He Xiao Lian Executives
Dong Fan Directors, Directors, and Executives
Ceng Kai Directors, executives
Tang Xian Min Directors, executives
Zhang Ming Yuan Secretary Dong
Fang Li Hua Supervisors
Zhang Guang Hai Directors, executives
Li De Zhi Executives
Lu Shao Zhang Executives

Jafron Biomedical Co (SZSE:300529) Headlines

No Headlines